5604 results
Refine Your Search
Targeting acetyl-CoA synthetase 2 to remodel obesity-evoked inflammatory microenvironment in myeloma
Our proposal aims to develop a novel strategy to improve therapeutic efficacy for patients with multiple myeloma by remodeling inflammatory microenvi…
Qing Yi
I am a translational tumor immunologist. I have years of experience as a and published researcher and am one of the leading investigators in the fie…
Developing Novel CAR-T Cell Therapy For Hematologic Malignancies
We observed that patients with many hematologic cancers expressed high levels of DKK1 and generated novel human DKK1-A2 cells that can kill cancer ce…
Development of mutant GTPase-specific degraders for peripheral T cell lymphoma treatment
This project aims to develop targeted therapies against peripheral T cell lymphoma (PTCL), a diverse group of aggressive blood cancers with poor clini…
Yubin Zhou
Dr. Yubin Zhou is a professor of Translational Cancer Research at the Texas A&M University Institute of Biosciences and Technology. He is interested i…
Discovery and therapeutic targeting of novel mechanisms driving Double Hit Lymphomas
lymphoma (DHL) is an aggressive form of diffuse large lymphoma (DLBCL) defined by MYC and BCL2 rearrangements. DHL has been linked to very poor outc…
Stephen Gottschalk
I am a pediatric oncologist, who is interested in using the patient’s immune system to fight cancer. I grew up in Germany and moved to the US in afte…
CD70-directed CAR T-cell therapy for the treatment of relapsed/refractory pediatric AML
In this project, we will test an innovative therapy called CAR therapy for children with a type of cancer called AML. In the laboratory, we have iden…
Inhibition of PKCβ as a strategy for BTK inhibitor refractory CLL
Patients with CLL that have progressed on BTK inhibitors have high risk disease with few clinical options. Here we propose a novel, selective inhibito…
Targeting GCK as a novel and selective therapeutic strategy against RAS mutated Multiple Myeloma
RAS/MAPK mutations are the key drivers in MM, which occurs in % of newly diagnosed and higher in relapsed MM patients. However, RAS remains undruggabl…
Mark Dawson
Professor Dawson is the Associate Director for Research Translation, a Program Head in Laboratory Research and a Consultant Haematologist at the Peter…
Understanding molecular determinants of immune evasion to CAR-T cells at single clone resolution
Cellular immunotherapies such cells are now firmly established as major pillars of therapy particularly in malignancies. However, despite their rem…
Strategic combinations to overcome therapeutic resistance and relapse in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most fatal type of leukemia and has a high rate of relapse following current therapies. We have recently uncovered…
Jenny Wang
I am Head of the Cancer and Stem Cell Laboratory, and my research has been focused on leukemia stem cell biology and targeted therapies in the past y…
Arming NK Cells to Target B7-H3+ AML Cells
In order to develop a novel immunotherapy approach to treating AML, we propose targeting B7-H3 (CD276), a promising immune checkpoint that has been re…
Wendy Stock
Dr. Stock is the Anjuli Seth Nayak Professor of Leukemia Research at the University of Chicago. She is the of the Leukemia Committee for the Alliance…
A phase 1b/2 study targeting apoptotic and signaling pathways in T-acute lymphoblastic leukemia
lymphoblastic leukemia () is an aggressive leukemia with limited treatment options after chemotherapy. Our preclinical work in animal models of demo…
Todd Fehniger
Dr. Fehniger is a that leads a research program focused on translational NK cell biology and therapy. His group pioneered studies characterizing (ML…
NK cell immunotherapy to reduce relapse after haploidentical transplant for high-risk pediatric AML
Leukemia recurrence remains the most common type of treatment failure after allogeneic hematopoietic cell transplant for children and young adults wit…
William Matsui
William Matsui is a Professor of Oncology, Director of the Hematologic Malignancy Program, Associate Chair of Research, and the Deputy Director of the…
Stem cell features and Notch signaling in p53 deleted multiple myeloma
We have investigated the consequences of p53 loss on stem cell properties, namely clonogenic growth, , and drug resistance in multiple myeloma. We hav…
Roland Walter
Dr. Walter’s research focuses on AML. He is particularly interested in improving therapies by optimizing existing therapeutics and through the develo…
211Astatine-CD123 Radioimmunotherapy for Cancer (Stem) Cell-Directed Treatment of Acute Leukemia
Because acute leukemias are very sensitive to radiation, radioisotopes are ideal payloads to arm antibodies against these , aggressive blood cancers. …
THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) INVESTS $3.8 MILLION TO ADVANCE HEALTH EQUITY
LLS’s Equity in Access Research Program Awards Five New Grants to Researchers Across the U.S. Aiming to Break Down Barriers to Care for Blood Cancer P…
News Release
LLS, advocates celebrate major state policy wins for patients
While Congress meets , state legislatures typically meet only in the first half of the year. The start of the summer generally marks the end of the st…